Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Other financing activities: 2012-2024

Historic Other financing activities for Ani Pharmaceuticals (ANIP) over the last 7 years, with Dec 2024 value amounting to $2.0 million.

  • Ani Pharmaceuticals' Other financing activities was N/A to $2.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was $2.0 million, marking a year-over-year change of. This contributed to the annual value of $17.4 million for FY2024, which is N/A change from last year.
  • As of Q4 2024, Ani Pharmaceuticals' Other financing activities stood at $2.0 million, which was up 386.52% from -$690,000 recorded in Q4 2022.
  • Ani Pharmaceuticals' Other financing activities' 5-year high stood at $13.6 million during Q4 2021, with a 5-year trough of -$690,000 in Q4 2022.
  • Over the past 2 years, Ani Pharmaceuticals' median Other financing activities value was $203,000 (recorded in 2022), while the average stood at $395,200.
  • Within the past 5 years, the most significant YoY rise in Ani Pharmaceuticals' Other financing activities was 48,400.00% (2022), while the steepest drop was 105.06% (2022).
  • Over the past 4 years, Ani Pharmaceuticals' Other financing activities (Quarterly) stood at $169,000 in 2020, then spiked by 7,966.27% to $13.6 million in 2021, then tumbled by 105.06% to -$690,000 in 2022, then reached $2.0 million in 2024.
  • Its last three reported values are $2.0 million in Q4 2024, -$690,000 for Q4 2022, and $483,000 during Q3 2022.